Rhelion Life Sciences Corp. RHEL
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.23M | 2.49M | 2.45M | 2.37M | 2.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.23M | 2.49M | 2.45M | 2.37M | 2.83M |
| Cost of Revenue | 1.28M | 1.56M | 1.62M | 1.51M | 1.80M |
| Gross Profit | 951.20K | 937.40K | 827.30K | 866.90K | 1.03M |
| SG&A Expenses | 4.30M | 4.21M | 4.04M | 3.93M | 4.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 0.00 | 0.00 | -119.70K |
| Total Operating Expenses | 5.65M | 5.78M | 5.67M | 5.44M | 5.71M |
| Operating Income | -3.42M | -3.29M | -3.22M | -3.07M | -2.88M |
| Income Before Tax | -5.51M | -5.29M | -3.93M | -3.56M | -3.10M |
| Income Tax Expenses | -221.60K | -236.80K | -123.40K | -117.70K | -96.00K |
| Earnings from Continuing Operations | -5.29 | -5.05 | -3.81 | -3.44 | -3.01 |
| Earnings from Discontinued Operations | -280.60K | 85.30K | 85.30K | 85.30K | 85.30K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 544.50K | 541.00K | 169.50K | 179.40K | 180.40K |
| Net Income | -5.03M | -4.42M | -3.55M | -3.17M | -2.74M |
| EBIT | -3.42M | -3.29M | -3.22M | -3.07M | -2.88M |
| EBITDA | -3.22M | -3.09M | -2.95M | -2.72M | -2.46M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.81B | 1.67B | 1.65B | 1.63B | 1.62B |
| Average Diluted Shares Outstanding | 1.81B | 1.67B | 1.65B | 1.63B | 1.62B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |